title: Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.
abstract: We report on a case of reversible Pisa syndrome developed after treatment with galantamine in a patient with Alzheimer's disease without previous exposure to neuroleptic or other cholinesterase inhibitors. Complete and persistent resolution of the syndrome was achieved several weeks after botulinum toxin type-A injection.
authors.affiliation: Department of Neuroscience A.O.B. S. Michele General Hospital Cagliari, Sardinia, Italy. giovannicossu@aob.it
authors.forename: Giovanni
authors.initials: G
authors.lastname: Cossu
authors.forename: Maurizio
authors.initials: M
authors.lastname: Melis
authors.forename: Giannina
authors.initials: G
authors.lastname: Melis
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Maccioni
authors.forename: Valeria
authors.initials: V
authors.lastname: Putzu
authors.forename: Olga
authors.initials: O
authors.lastname: Catte
authors.forename: Paolo Francesco
authors.initials: PF
authors.lastname: Putzu
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy; D004421:Dystonia / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005702:Galantamine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009465:Neuromuscular Agents / Q000627:therapeutic use; D009483:Neuropsychological Tests; D012720:Severity of Illness Index; D013577:Syndrome
chemical_list: D002800:Cholinesterase Inhibitors; D009465:Neuromuscular Agents; D005702:Galantamine; D019274:Botulinum Toxins, Type A